Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine

ArticleinJournal of chromatography. B, Biomedical applications 677(1):123-32 · March 1996with28 Reads
DOI: 10.1016/0378-4347(95)00405-X · Source: PubMed

    Abstract

    A sensitive high-performance liquid chromatographic (HPLC) method is described for the determination of a new potent antihypertensive agent, TCV-116, and its two metabolites (M-I and M-II) in human serum or urine. After pre-treatment of the specimens, the analytes were determined using a column switching technique, except for the metabolites in urine which were determined by gradient elution mode HPLC. The quantitation limits for TCV-116, M-I and M-II were all 0.5 ng/ml in serum, and 0.5, 10 and 110 ng/ml in urine, respectively. The methods were applied to clinical trials of TCV-116.